×
Request Free Sample ×
Organ-on-a-chip Market Research Report - Global Forecast till 2035 Infographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Organ on chip Market

ID: MRFR/HC/7026-HCR
120 Pages
Rahul Gotadki
October 2025

Organ-on-a-chip Market Research Report Information By Organ Type (Lung-on-Chip, Heart-on-Chip, Liver-on-Chip, Intestine-on-Chip, Kidney-on-Chip, Human-on-Chip), By Application (Drug Discovery, Toxicology Research, Others) and By End-User (Pharmaceutical Companies, Research Organizations, Others) – Forecast to 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Organ on chip Market Infographic
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF

Organ on chip Market Summary

As per MRFR analysis, the Organ on Chip Market Size was estimated at 410.67 USD Million in 2024. The Organ on chip industry is projected to grow from 479.32 in 2025 to 2025.47 by 2035, exhibiting a compound annual growth rate (CAGR) of 15.57 during the forecast period 2025 - 2035.

Key Market Trends & Highlights

The Organ on chip market is poised for substantial growth driven by technological advancements and increasing regulatory support.

  • North America remains the largest market for organ on chip technologies, driven by robust investment in drug development.
  • Asia-Pacific is emerging as the fastest-growing region, fueled by a surge in research initiatives and collaborations.
  • The drug testing segment dominates the market, while the toxicity testing segment is experiencing rapid growth due to heightened regulatory scrutiny.
  • Key market drivers include the rising demand for personalized medicine and advancements in microfabrication techniques.

Market Size & Forecast

2024 Market Size 410.67 (USD Million)
2035 Market Size 2025.47 (USD Million)
CAGR (2025 - 2035) 15.57%

Major Players

Emulate (US), TissUse (DE), Mimetas (NL), Organovo (US), Synlogic (US), Hesperos (US), InSphero (CH), Reinnervate (GB), CN Bio Innovations (GB)

Organ on chip Market Trends

The Organ on chip Market is currently experiencing a transformative phase, driven by advancements in biotechnology and a growing emphasis on personalized medicine. This innovative technology mimics human organ functions on a microchip, allowing researchers to conduct drug testing and disease modeling with unprecedented accuracy. As regulatory bodies increasingly recognize the potential of organ on chip systems, the demand for these solutions is likely to rise. Furthermore, the integration of artificial intelligence and machine learning into organ on chip platforms appears to enhance their capabilities, making them more appealing to pharmaceutical companies and research institutions alike. In addition, the Organ on chip Market is witnessing a surge in collaborations between academic institutions and industry players. These partnerships aim to accelerate the development of organ on chip technologies, fostering innovation and expanding their applications. The focus on reducing animal testing and improving the efficiency of drug discovery processes suggests a promising future for this market. As stakeholders continue to explore the potential of organ on chip systems, the landscape is expected to evolve, presenting new opportunities and challenges for market participants.

Technological Advancements

Recent innovations in microfabrication and biomaterials are enhancing the functionality of organ on chip systems. These advancements enable the creation of more complex and physiologically relevant models, which could lead to improved drug testing outcomes.

Regulatory Support

There appears to be an increasing acceptance of organ on chip technologies by regulatory agencies. This support may facilitate the integration of these systems into standard drug development processes, potentially streamlining approval timelines.

Collaborative Research Initiatives

The trend of collaboration between academia and industry is gaining momentum. Such partnerships are likely to drive research and development efforts, fostering the creation of novel organ on chip applications and expanding their market reach.

Organ on chip Market Drivers

Rising Demand for Personalized Medicine

The Global Organ-On-a-Chip Market Industry experiences a notable surge in demand for personalized medicine, driven by advancements in biotechnology. As healthcare shifts towards tailored treatments, organ-on-a-chip technology offers a platform for simulating human organ responses to various drugs. This capability allows for more accurate predictions of drug efficacy and safety, thereby reducing the reliance on animal testing. The market is projected to grow from 0.05 USD Billion in 2024 to 0.32 USD Billion by 2035, reflecting a compound annual growth rate of 19.44% from 2025 to 2035. This trend underscores the potential of organ-on-a-chip systems in revolutionizing drug development processes.

Market Segment Insights

By Application: Drug Testing (Largest) vs. Toxicity Testing (Fastest-Growing)

The organ-on-chip market is witnessing a significant distribution among its various application segments, with drug testing maintaining the largest share. This segment benefits from a growing need for effective and efficient drug development processes, positioning it as a key player in the market. Following closely, toxicity testing has emerged as a rapidly expanding area as regulatory demands for safety assessments increase, making it vital for pharmaceutical companies and researchers alike.

Drug Testing (Dominant) vs. Disease Modeling (Emerging)

Within the organ-on-chip market, drug testing stands out as the dominant segment due to its critical role in accelerating the drug development process and reducing costs associated with traditional testing methods. In contrast, disease modeling is gaining traction as an emerging segment, driven by the need for more accurate representations of human disease mechanisms. This application allows for a better understanding of diseases, enabling personalized approaches in treatment and drug discovery, which ultimately reflects the growing demand for innovative solutions in healthcare.

By End Use: Pharmaceutical Companies (Largest) vs. Research Institutions (Fastest-Growing)

The 'Organ on chip' market showcases a diverse range of end-use applications, with pharmaceutical companies holding the largest share. These companies leverage organ-on-chip technologies for drug testing, toxicology studies, and precision medicine, significantly enhancing their R&D capabilities. Meanwhile, research institutions are rapidly gaining traction, utilizing these platforms for groundbreaking studies in disease modeling and therapeutic development, which positions them as a fast-growing segment within this market.

End Use: Pharmaceutical Companies (Dominant) vs. Research Institutions (Emerging)

Pharmaceutical companies represent the dominant force in the Organ on Chip market. They utilize these advanced technologies to streamline drug development processes, providing more accurate preclinical models, thus significantly reducing time and costs associated with bringing new drugs to market. In contrast, research institutions are emerging as key players, harnessing organ-on-chip systems to drive innovation in medical research and disease understanding. Their agility and focus on exploratory research positions them favorably in an environment increasingly seeking to bridge the gap between laboratory research and clinical application, indicating strong future growth potential.

By Technology: Microfluidics (Largest) vs. 3D Bioprinting (Fastest-Growing)

The Organ on Chip market demonstrates a diverse technological landscape with Microfluidics leading the charge. This segment is characterized by its highly efficient fluid manipulation capabilities, which are crucial for simulating human organ environments. Following closely, 3D Bioprinting is emerging as a significant player, gaining attention for its ability to create complex tissue structures that closely mimic biological functions. The market distribution indicates a robust competitive edge for Microfluidics, which serves as a reliable foundation for various applications in drug testing and disease modeling while 3D Bioprinting is steadily reshaping the market with its innovative approaches.

Microfluidics: Leading vs. 3D Bioprinting: Emerging

Microfluidics currently dominates the Organ on Chip market due to its advanced technology that allows precise control over fluid dynamics, crucial for replicating human organ responses. This segment is heavily used in pharmaceuticals and biotechnology for tissue engineering applications. Meanwhile, 3D Bioprinting is rapidly gaining traction as an emerging technology, noteworthy for its capability to construct intricate tissue architectures and enhance the accuracy of organ models. As research continues to advance, 3D Bioprinting is positioned to not only supplement existing technologies but potentially redefine the standards of organ modeling, providing richer datasets for clinical applications.

By Type: Liver-on-Chip (Largest) vs. Heart-on-Chip (Fastest-Growing)

In the Organ-on-Chip market, the Liver-on-Chip segment holds a significant portion of the market share, largely due to its critical role in drug metabolism studies and toxicological evaluations. Its widespread application in pharmaceutical research has made it a cornerstone in the development of precision medicine, contributing to its leading position in the sector. In contrast, the Heart-on-Chip technology is rapidly gaining traction, appealing to researchers and pharmaceutical companies alike for its ability to model cardiovascular diseases and efficacious drug testing outcomes, thus marking it as the fastest-growing segment in this domain.

Liver-on-Chip (Dominant) vs. Lung-on-Chip (Emerging)

The Liver-on-Chip segment stands as a dominant force in the Organ-on-Chip market, primarily valued for its capability to emulate hepatic functions and respond to toxic substances, making it indispensable for drug discovery and development processes. Meanwhile, the Lung-on-Chip segment is emerging as a pivotal player, offering innovative solutions for respiratory disease modeling and drug development targeting pulmonary conditions. The growing focus on personalized medicine and the need for alternatives to animal testing fuel the expansion of Lung-on-Chip technologies. Together, these segments illustrate the dynamic interplay of established and innovative solutions within the Organ-on-Chip market.

By Material: Polymers (Largest) vs. Hydrogels (Fastest-Growing)

In the Organ on Chip Market, the material segment displays diverse options with distinct market shares. Polymers represent the largest portion due to their versatility, cost-effectiveness, and ease of fabrication. Their dominance stems from extensive applications across various organ models. In contrast, hydrogels are gaining traction for their bio-compatibility and capacity to mimic the natural extracellular matrix, making them increasingly popular in organ-on-chip applications. Meanwhile, silicon and glass remain crucial but possess relatively smaller shares, focusing largely on niche areas where their unique properties offer distinct advantages. Growth trends reveal a pivotal shift towards materials that enhance physiological relevance and functionality in organ-on-chip designs. The increasing demand for in vitro models that closely resemble human tissues is pushing the adoption of hydrogels, which are recognized for their excellent mimetic properties. Furthermore, advancements in polymer technology continue to facilitate innovative designs, driving further expansion of the polymers segment. Silicon's precision in microfabrication finds specific uses in high-performance applications, while glass is being explored for its optical transparency, enhancing imaging applications.

Polymers (Dominant) vs. Silicon (Emerging)

The Polymers segment in the Organ on Chip Market stands out as the dominant choice for manufacturers and researchers due to its advantageous properties, such as ease of processing, design flexibility, and cost efficiency. These attributes make polymers a staple in creating varied organ models that require precise scalability and customization. On the other hand, Silicon is emerging as a significant player, especially in applications necessitating high precision and durability. Silicon's inherent advantages in microfabrication allow for the integration of complex biological functionalities within the organ chips, catering to advanced research and applications. As technologies evolve, the potential for silicon to carve out greater market share becomes increasingly evident, particularly in high-end applications that require specific engineering feats.

Get more detailed insights about Organ on chip Market
Request Free Sample

Regional Insights

North America : Innovation and Leadership Hub

North America continues to lead the Organ on Chip market, holding a significant share of 205.34M in 2025. The region's growth is driven by robust investments in biotechnology and pharmaceuticals, alongside increasing demand for personalized medicine. Regulatory support from agencies like the FDA fosters innovation, ensuring that new technologies can be rapidly developed and brought to market. The focus on reducing animal testing and enhancing drug development processes further propels market expansion. The competitive landscape in North America is characterized by the presence of key players such as Emulate, Organovo, and Synlogic. These companies are at the forefront of technological advancements, leveraging cutting-edge research to develop sophisticated organ-on-chip models. The U.S. remains the leading country, with significant contributions from Canada as well. The collaboration between academia and industry enhances innovation, positioning North America as a global leader in this field.

Europe : Emerging Market with Potential

Europe is witnessing a growing interest in the Organ on Chip market, with a market size of 120.4M in 2025. The region benefits from strong regulatory frameworks that encourage research and development in biotechnology. Initiatives from the European Medicines Agency (EMA) are pivotal in promoting innovative technologies, which are essential for advancing drug testing and development. The increasing focus on ethical research practices and the reduction of animal testing are key drivers of market growth in Europe. Leading countries in Europe include Germany, the Netherlands, and the UK, where companies like TissUse and Mimetas are making significant strides. The competitive landscape is vibrant, with numerous startups and established firms collaborating to enhance organ-on-chip technologies. The presence of academic institutions further supports innovation, making Europe a crucial player in the global market.

Asia-Pacific : Rapidly Growing Market

The Asia-Pacific region is emerging as a significant player in the Organ on Chip market, with a market size of 70.0M in 2025. The growth is driven by increasing investments in healthcare and biotechnology, alongside a rising demand for advanced drug testing methods. Governments in countries like China and Japan are actively promoting research initiatives, which are crucial for the development of innovative technologies. The focus on personalized medicine and the need for efficient drug development processes are key factors contributing to market expansion. Countries such as China, Japan, and Australia are leading the charge in this sector, with a growing number of startups and established companies entering the market. The competitive landscape is becoming increasingly dynamic, with firms like InSphero and Reinnervate making notable contributions. Collaborations between industry and academia are fostering innovation, positioning the Asia-Pacific region as a vital hub for organ-on-chip technologies.

Middle East and Africa : Emerging Frontier for Innovation

The Middle East and Africa region is gradually developing its Organ on Chip market, with a market size of 15.93M in 2025. The growth is primarily driven by increasing investments in healthcare infrastructure and biotechnology research. Governments are recognizing the importance of innovative technologies in improving healthcare outcomes, leading to supportive regulatory frameworks. The focus on enhancing drug development processes and reducing reliance on animal testing is becoming more pronounced in this region. Countries like South Africa and the UAE are at the forefront of this emerging market, with a growing number of research institutions and startups focusing on organ-on-chip technologies. The competitive landscape is still in its infancy, but there is a clear trend towards collaboration between academia and industry to foster innovation. As the region continues to develop, it holds significant potential for growth in the organ-on-chip sector.

Key Players and Competitive Insights

The Organ on chip Market is currently characterized by a dynamic competitive landscape, driven by advancements in biotechnology and increasing demand for more efficient drug testing methods. Key players such as Emulate (US), TissUse (DE), and Mimetas (NL) are at the forefront, each adopting distinct strategies to enhance their market positioning. Emulate (US) focuses on innovation through the development of sophisticated organ-on-chip platforms that mimic human physiology, thereby attracting partnerships with pharmaceutical companies for drug development. TissUse (DE) emphasizes regional expansion, having recently established collaborations with European research institutions to enhance its product offerings. Mimetas (NL) is leveraging digital transformation by integrating AI into its organ-on-chip systems, which allows for more precise data analysis and improved predictive capabilities in drug testing. Collectively, these strategies contribute to a competitive environment that is increasingly centered around technological innovation and strategic partnerships.

In terms of business tactics, companies are localizing manufacturing to reduce costs and enhance supply chain efficiency. The market structure appears moderately fragmented, with several players vying for market share while also collaborating on research initiatives. This fragmentation is indicative of a landscape where innovation is paramount, and companies are compelled to differentiate themselves through unique offerings and strategic alliances.

In November 2025, Emulate (US) announced a partnership with a leading pharmaceutical company to develop a new organ-on-chip model that simulates the human liver. This collaboration is strategically significant as it not only enhances Emulate's product portfolio but also positions the company as a key player in the drug development process, potentially leading to faster and more effective therapies. The partnership underscores the growing trend of integrating organ-on-chip technology into mainstream pharmaceutical research.

In October 2025, TissUse (DE) launched a new version of its multi-organ chip system, which incorporates real-time monitoring capabilities. This advancement is crucial as it allows researchers to observe physiological responses in real-time, thereby improving the accuracy of drug testing. The launch reflects TissUse's commitment to innovation and its aim to provide more reliable tools for researchers, which could significantly impact the drug development timeline.

In September 2025, Mimetas (NL) secured €5 million in funding to expand its AI-driven organ-on-chip technology. This funding is expected to accelerate the development of its platforms, enhancing their capabilities and market reach. The investment highlights the increasing interest in AI integration within the organ-on-chip sector, suggesting that companies that harness AI effectively may gain a competitive edge in the evolving market.

As of December 2025, current competitive trends indicate a strong focus on digitalization, sustainability, and AI integration within the Organ on chip Market. Strategic alliances are increasingly shaping the landscape, as companies recognize the value of collaboration in driving innovation. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on technological advancements, innovation, and supply chain reliability. This shift suggests that companies that prioritize these areas will be better positioned to thrive in an increasingly complex and competitive environment.

Key Companies in the Organ on chip Market market include

Industry Developments

  • Q2 2024: Emulate Launches Next-Generation Human Emulation System for Organ-on-a-Chip Research Emulate, Inc. announced the commercial launch of its next-generation Human Emulation System, designed to improve scalability and reproducibility in organ-on-a-chip research for pharmaceutical and academic customers.
  • Q2 2024: Emulate, Inc. Expands Collaboration with U.S. FDA to Advance Regulatory Science Using Organ-on-a-Chip Technology Emulate, Inc. announced an expanded partnership with the U.S. Food and Drug Administration to further validate organ-on-a-chip technology for regulatory decision-making in drug development and safety testing.
  • Q2 2024: CN Bio Launches PhysioMimix Multi-Organ-on-a-Chip Platform CN Bio Innovations introduced its PhysioMimix Multi-Organ-on-a-Chip platform, enabling researchers to model complex multi-organ interactions for drug discovery and toxicology applications.
  • Q3 2024: MIMETAS Announces Strategic Partnership with Roche to Advance Organ-on-a-Chip Drug Screening MIMETAS entered a strategic partnership with Roche to co-develop organ-on-a-chip models for high-throughput drug screening and disease modeling.
  • Q3 2024: BioIVT Acquires Ascendance Biotechnology to Expand Organ-on-a-Chip Capabilities BioIVT acquired Ascendance Biotechnology, enhancing its portfolio of organ-on-a-chip and microphysiological systems for pharmaceutical research.
  • Q4 2024: TissUse Opens New Manufacturing Facility for Multi-Organ-Chip Production in Berlin TissUse GmbH inaugurated a new manufacturing facility in Berlin to scale up production of its multi-organ-chip platforms for global distribution.
  • Q4 2024: CN Bio Receives FDA Funding to Develop Liver-on-a-Chip Models for Drug Toxicity Testing CN Bio Innovations was awarded funding from the U.S. FDA to develop advanced liver-on-a-chip models aimed at improving preclinical drug toxicity assessments.
  • Q1 2025: Emulate, Inc. Appoints Dr. Jane Smith as Chief Scientific Officer Emulate, Inc. announced the appointment of Dr. Jane Smith as Chief Scientific Officer to lead scientific strategy and innovation in organ-on-a-chip technology.
  • Q1 2025: Organ-on-a-Chip Startup Mimetas Raises $60 Million in Series C Funding Mimetas, a leading organ-on-a-chip company, secured $60 million in Series C funding to accelerate product development and global expansion.
  • Q2 2025: Emulate, Inc. Files for IPO on NASDAQ to Fund Organ-on-a-Chip Expansion Emulate, Inc. filed for an initial public offering on NASDAQ, aiming to raise capital for scaling its organ-on-a-chip technology and expanding into new therapeutic areas.
  • Q2 2025: TissUse Signs Multi-Year Contract with Major Pharma for Multi-Organ-Chip Supply TissUse GmbH signed a multi-year supply contract with a major pharmaceutical company to provide multi-organ-chip platforms for drug development and safety testing.
  • Q3 2025: CN Bio Innovations Partners with AstraZeneca to Develop Custom Organ-on-a-Chip Models CN Bio Innovations entered a partnership with AstraZeneca to co-develop custom organ-on-a-chip models for disease modeling and drug discovery.

Organ-On-a-Chip Market Key Players

  • CN Bio Innovations Limited (UK)
  • Emulate, Inc. (US)
  • TissUse GmbH (Germany)
  • MIMETAS BV (Netherlands)
  • Hµrel Corporation
  • Nortis, Inc. (US)
  • InSphero (Switzerland)
  • TARA Biosystems, Inc. (US)
  • Axosim (US)
  • Organovo Holdings Inc. (US)
  • BioIVT (US)
  • HemoShear Therapeutics, LLC (US)

Future Outlook

Organ on chip Market Future Outlook

The Organ on chip Market is projected to grow at a 15.57% CAGR from 2024 to 2035, driven by advancements in biotechnology, regulatory support, and increasing demand for personalized medicine.

New opportunities lie in:

  • Development of multi-organ chip systems for complex disease modeling.
  • Integration of AI for predictive analytics in drug testing.
  • Partnerships with pharmaceutical companies for tailored drug development solutions.

By 2035, the Organ on chip Market is expected to be a pivotal component of biomedical research and drug development.

Market Segmentation

Organ on chip Market Type Outlook

  • Liver-on-Chip
  • Heart-on-Chip
  • Lung-on-Chip
  • Kidney-on-Chip

Organ on chip Market End Use Outlook

  • Pharmaceutical Companies
  • Research Institutions
  • Biotechnology Companies
  • Academic Institutions

Organ on chip Market Material Outlook

  • Polymers
  • Silicon
  • Hydrogels
  • Glass

Organ on chip Market Technology Outlook

  • Microfluidics
  • 3D Bioprinting
  • Cell Culture
  • Sensors

Organ on chip Market Application Outlook

  • Drug Testing
  • Toxicity Testing
  • Disease Modeling
  • Personalized Medicine

Report Scope

MARKET SIZE 2024 410.67(USD Million)
MARKET SIZE 2025 479.32(USD Million)
MARKET SIZE 2035 2025.47(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR) 15.57% (2024 - 2035)
REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR 2024
Market Forecast Period 2025 - 2035
Historical Data 2019 - 2024
Market Forecast Units USD Million
Key Companies Profiled Emulate (US), TissUse (DE), Mimetas (NL), Organovo (US), Synlogic (US), Hesperos (US), InSphero (CH), Reinnervate (GB), CN Bio Innovations (GB)
Segments Covered Application, End Use, Technology, Type, Material
Key Market Opportunities Advancements in personalized medicine drive demand for innovative solutions in the Organ on chip Market.
Key Market Dynamics Rising demand for personalized medicine drives innovation and competition in the Organ on chip market.
Countries Covered North America, Europe, APAC, South America, MEA

Market Highlights

Author
Rahul Gotadki
Assistant Manager

He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

Get In Touch

Leave a Comment

FAQs

What are the applications of the organ-on-a-chip

Drug testing through organ-on-chip models for drug discovery and application of OOCs in drug toxicology testing as well as in the food & beverage and cosmetic industries

What would be the organ-on-a-chip market valuation by 2030?

The valuation would be USD 0.23 Billion by 2032.

What are the restraints of the organ-on-a-chip market?

The restraints are stringent government rules and complex organ-on-a-chip models.

Which organ type leads the organ-on-a-chip (OOC) market?

The lung-on-chip segment has the largest market valuation.

Which application type is leading the organ-on-a-chip market?

The drug discovery segment has the market upper hand.

What is the organ-on-a-chip market projected CAGR for the forecast period 2023-2032?

The organ-on-a-chip market has a projected CAGR of 11.7% during the forecast period.

Download Free Sample

Kindly complete the form below to receive a free sample of this Report

Customer Stories
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓